Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 17 ... by a two-week non-treatment period, produced clearance rates superior to placebo for actinic keratosis (AK). Imiquimod 3.75% was also more effective than 2.5% with comparable safety. The new ...
2009 OCT 12 ... of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial,' are ...
2009 OCT 12 ... showed keratin-filled endophytic epithelial-lined invaginations, one with a coexistent actinic keratosis. The fourth biopsy specimen revealed an invasive squamous cell carcinoma with ...
2009 SEP 28 ... period in PDT by ionizing ALA using direct-current pulsed iontophoresis to treat actinic keratosis (AK)." "Twenty percent ALA solution was applied to AK lesions of five ...
2009 NOV 23 ... Peplin's lead product candidate, PEP005 Gel is currently in Phase 3 clinical trials for actinic (solar) keratosis (AK), a common pre-cancerous skin lesion, on both head and non-head ...
2009 SEP 14 ... Peplin team over the past several years to advance our lead candidate PEP005 Gel for actinic keratosis through to near completion of Phase 3 clinical trials. We are pleased LEO recognises the ...
2009 NOV 2 ... is lending his voice to a national public education program to raise awareness of actinic keratosis (AK) -- a potential early warning sign of skin cancer -- as well as the long-term ...
2009 SEP 14 ... complete Phase 3 clinical trials for its lead product, PEP005 (ingenol mebutate) Gel for actinic (solar) keratosis (AK). The company is confident it will have access to sufficient ...
2009 SEP 14 ... emphasis on the most current therapeutic options for each lesion. Recent findings Actinic keratosis can now be treated with photodynamic therapy or with many topical agents, as ...
2009 NOV 16 ... "However, they have not been examined in the SCC precursor lesions, Bowen disease or actinic keratosis. Here, we present a novel study of mtDNA D-loop mutations in these two precursors, a ...
2009 SEP 28 ... situ skin tumors, increased SIRs of 1.95-4.30 for squamous cell, Bowen's disease, and actinic keratosis were observed for individuals with affected siblings or parents, and SIRs were generally ...
2009 NOV 9 ... therapy with topical 5-aminolevulinic acid is an effective and safe treatment for actinic keratosis and superficial non-melanoma skin cancer. Further, some studies have reported good ...
2009 NOV 9 ... "The incidence of photodamaged skin and skin lesions of all degrees of severity, from actinic keratosis (AK) to skin cancers, has dramatically increased. actinic keratoses are pathologic, ...
2009 NOV 17 ... (25%) were associated with other cutaneous lesions, which included basal cell carcinoma, actinic keratosis, desmoplastic malignant melanoma, junctional melanocytic nevus, tricholemmoma, and ...
2009 JUL 20 ... diagnosis of non-melanoma skin cancer (NMSC). To describe OCT features in NMSC such as actinic keratosis (AK) and basal cell carcinoma (BCC) and in benign lesions and to assess the diagnostic ...
2009 AUG 31 ... a study "To identify criteria for the diagnosis of squamous cell carcinoma (SCC) and actinic keratosis (AK) by in vivo reflectance confocal microscopy (RCM). Prospective RCM imaging of ...
2009 AUG 24 ... growing incident rates of skin cancer and their corresponding precursor lesions, e. g. actinic keratosis (AK), among Caucasians have become an important public health problem. A multicenter ...
